Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization (2016 - 2025)
Biomarin Pharmaceutical (BMRN) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $79.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 17.49% year-over-year to $79.6 million, compared with a TTM value of $79.6 million through Dec 2025, down 17.49%, and an annual FY2025 reading of $79.6 million, down 17.49% over the prior year.
- Accumulated Depreciation & Amortization was $79.6 million for Q4 2025 at Biomarin Pharmaceutical, up from $59.1 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $108.0 million in Q4 2021 and bottomed at $22.1 million in Q1 2025.
- Average Accumulated Depreciation & Amortization over 5 years is $62.2 million, with a median of $57.2 million recorded in 2021.
- The sharpest move saw Accumulated Depreciation & Amortization rose 7.88% in 2021, then decreased 24.49% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $108.0 million in 2021, then fell by 5.62% to $102.0 million in 2022, then increased by 2.37% to $104.4 million in 2023, then dropped by 7.63% to $96.4 million in 2024, then dropped by 17.49% to $79.6 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for BMRN at $79.6 million in Q4 2025, $59.1 million in Q3 2025, and $40.6 million in Q2 2025.